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Summ_ar The relation between pretreatment night-time urinary catecholamine excretion and chemotherapy-
induced nausea and vomiting was studied. The first cohort included 17 women and three men with various
cancer forms receiving low or moderately emetogenic chemotherapy. The second cohort included 42 women
receiving cisplatinum (50 mg m-2) for ovarian cancer and ondansetron as an antiemetic (8 mg i.v. x 3 at
chemotherapy and 8 mg p.o. x 3 for 5 days). Relatively higher noradrenaline, but not adrenaline. excretion
was associated with an increased intensity of delayed nausea following treatment. Vomiting was not con-
sistently related to the excretion of either catecholamine. The results indicate that noradrenaline modulates
delayed nausea resulting from chemotherapy.
Nausea and vomiting are among the most common and
distressing side-effects of cancer chemotherapy (Lazlo &
Lucas. 1981: Johansson et al.. 1992). They may promote
complications such as anorexia, dehydration and electrolyte
imbalance (Harris. 1978; Durant. 1984). The mechanism
behind acute nausea and vomiting is partly understood, and
effective treatments include 5HT3-receptor blockade and cor-
ticosteroids (Smith et al.. 1990). On the other hand.
knowledge about delayed emesis, emesis 24 h or more after
chemotherapy. is sparse (Andrews & Davis, 1993). The effect
of, for example, 5HT3-receptor blockade on this condition
remains uncertain.
Multifactorial mechanisms relate chemotherapy to nausea
and vomiting. There is evidence that complex brainstem and
neocortical neuronal reflex systems partly under neuro-
humoral influences mediate nausea and vomiting (Jenkins &
Lahay. 1971; Fredrikson et al., 1992; Hursti et al., 1993). A
functional area in the lateral reticular formation at about the
level of the olivary nuclei of the medulla oblongata has been
termed 'the vomiting centre'. Anatomically, it probably con-
sists of the area postrema and the nucleus of the tractus
solitarius and their projections to the parabrachial nuclei and
the hypothalamus (Leslie & Reynolds, 1993). Apart from
regulating retching and vomiting, this functional system is
held to mediate changes in autonomic activity such as saliva-
tion. cutaneous vasoconstriction, pupillary dilatation, gastric
acid secretion and gut motility. The functional 'centre' is
activated by a coordinating system involving a variety of
anatomical organs and systems (Borison. 1974, 1981). Neuro-
pathways from the limbic system and the cerebrum may be
involved, and 'the vomiting centre' also receives input from
neocortical areas, the vestibular system, the gastrointestinal
tract, the gut and the spinal nerves.
The chemoreceptor trigger zone, a structure in or near the
area postrema. located bilaterally on the floor of the fourth
ventricle. is also functionally involved in emesis. The
blood-brain barrier does not operate in this area (Borison,
1974. 1981) and the structure is exposed to cerebrospinal
fluid as well as circulating blood. Neurons from the chemo-
receptor trigger zone project to the inside of the blood-brain
barrier. The chemoreceptor trigger zone has been implicated
as a sensor of chemotherapeutic agents, and its sensitivity
may be modulated by circulating hormones.
Catecholamines have been suggested to have a role in the
neurohumoral control of nausea and vomiting since they may
sensitise the area postrema to emetogenic substances (Leslie
& Reynolds. 1993; Andrews et al.. 1988). The area postrema
contains a-adrenergic reeceptors (Beleslin, 1992), and nor-
adrenaline is found in high concentrations in this region
(Leslie & Reynolds, 1993). m.-Adrenoreceptors subserving
emesis have also been located in the nucleus of the tractus
solitanrus (Beleslin. 1992). Drugs that act on central a-
adrenergic receptors produce emesis (Jenkins & Lahay, 1971;
Borison, 1989). In cats, for example. there is a profound
emetic response to noradrenaline infusion that is abolished
by blockade of a.-adrenoceptors (Beleslin & Strbac. 1987). It
is not known whether endogenous catecholamines likewise
modulate the activity of area postrema to influence nausea
and vomiting. Borison (1984) suggested that noradrenaline
would sensitise the area postrema to emetogenic substances.
To the extent that endogenous catecholamines in part
mediate individual differences in nausea and vomiting.
catecholamine levels should be associated with chemo-
therapy-induced nausea and vomiting.
The purpose of the present study was to examine whether
individual differences in endogenous catecholamine excretion
predict acute (0-24 h after chemotherapy) and delayed
(24-48 h after chemotherapy) nausea and vomiting in cancer
patients receiving chemotherapy. The relative importance of
adrenaline and noradrenaline is not well studied and we
included measures of both.
Materials and methods
Patients
Data were included from two cohorts, one receiving low or
moderately emetogenic and the other receiving highly
emetogenic therapy. Table I summarises the clinical features
of all patients.
Cohort I Twenty-one consecutive outpatients and three in-
patients receiving chemotherapy at the Karolinska Hospital
were included. Patients having received chemotherapy within
1 year were excluded, as were patients on opioid analgesics.
Four patients were ineligible for analysis: one patient failed
to complete urine sampling and three failed to report nausea
and vomiting. The remaining 20 patients (17 women and 3
men) had an average age of 50.6 years with a range of 35-76
years. Patients in cohort 1 had either cancer of the breast or
gastrointestinal tract or lymphoma (Table I). The most com-
mon chemotherapy regimen was CMF (cyclophosphamide.
methotrexate and 5-fluorouracil). Twelve patients received no
antiemetic treatment.
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Table I Cancer diagnosis. chemotherapy and antiemetic sedative agents
Number of
patients Cancer diagnosis Chemotherapy agents Antiemetic sedative agents
Cohort 1
12 Breast C+MTX+5-FU (n=5) Dix+Beta (n=2)
5-FU+ Dox±C (n = 6) Dix+ Beta (n = 2). Mp (n =1)
5-FU+ Mi (n=1) Mc
5 Gastrointestinal 5-FU + F Dix + Beta + Mc (n = I)
3 Lymphoma Dox+V+C+E (n =2) Dix+ Beta (n = 1)
Mu+O+N. +Pr (n1)
Cohort 2
42 Ovarian cancer Cis + Dox + Mel (n = 31) Ond + Dex (n = 17)
Ond + placebo (n = 14)
Cis + Dox (n =1) Ond + Dex (n = 8)
Ond + placebo (n = 3)
Cytotoxic agents: C. cyclophosphamide; Cis. cisplatin; Dox, doxorubicin, E, etoposide; F. folinate: 5-FU,
5-fluorouracil; Mel. melphalan; MTX, methotrexate: Mi, mitomycin: Mu. mustin: N. natulanar; Pr.
prednisolone: P. procarbazine: V, vincristine. Antiemetic sedative agents: Beta, dinatrium betamethasone:
Dex. dexamethasone: Dix. dixyrazin: Mp. methylprednisolone; Mc. metoclopramide; Ond. ondansetron.
Cohort 2 Cohort 2 comprises 42 inpatients receiving cis-
platinum (50 mgm-') for ovarian cancer at the Karolinska
Hospital. All patients were eligible for analysis. They had an
average age of 53.6 years with a range of 39-74 years. As
antiemetic medication, patients received ondansetron
(8 mg i.v. x 3) and were randomised to combine ondansetron
with either dexamethasone (20 mg i.v. x 1) or placebo given
6 h after the cisplatin infusion was started (Table I). Addi-
tionally. all patients received ondansetron (8 mg p.o. x 3) for
5 days after chemotherapy.
Procedure
Catecholamine excretion Identical procedures were used for
both cohorts. Patients were asked to refrain from coffee.
alcoholic beverages, bananas and products containing vanilla
from the evening prior to chemotherapy until chemotherapy
completion. The night before the start of the second
chemotherapy cycle. the urinary sample was collected in a
plastic container with sodium sulphite as antioxidant and
included the volume from the time of voiding before going to
bed until the time of rising (typically between 06.00 and
07.30 h). Volume and collection time were noted. The speci-
mens were acidified with 2 N hydrochloric acid to pH 3 and
stored at - 18'C until analysed for adrenaline and nor-
adrenaline. All samples were analysed by high-performance
liquid chromatography (Riggin & Kissinger. 1977; Hjemdahl
et al., 1989). Excretion rate was expressed in pmol min-'.
Nausea and vomiting Similar but not identical nausea rating
procedures were undertaken in cohorts 1 and 2. On the day
of their second chemotherapy course all patients rated nausea
on a 100 mm visual analogue scale (VAS). A zero score is
anchored at the left end with 'no nausea at all' and a
maximum score of 100 denotes 'worst possible nausea'. Self-
reports of nausea (VAS) and vomiting were given during
(one report) and after (two reports) infusion on the treatment
day. Patients also reported their nausea and vomiting every
6 h for the following 2 days.
Since patients in cohort 2 received a more emetogenic
therapy than patients in cohort 1, a median split approach
was adopted to relate nausea and vomiting to catecholamine
excretion separately for each cohort. On the first and second
day after chemotherapy, patients in cohort 1 continued to
rate their nausea on a visual analogue scale and the median
split approach was adopted to define the 'high' and 'low'
nausea groups. During the same period, patients in cohort 2
rated their nausea using four categories: no. mild, moderate
and severe nausea. No and mild nausea were grouped to
form the group with 'low' nausea, while moderate and severe
nausea were grouped to form the group with 'high' nausea.
Therefore, the distribution of patients is not symmetrical in
the 'low' and 'high' nausea groups. Emetic episodes were
counted by the patients during the chemotherapy day and
over the first and second days after chemotherapy.
Statistical analyses
Medians were calculated separately for each group. and those
with relatively lower values were grouped separately to form
groups 'low' in nausea or catecholamine excretion, while
those with relatively higher values formed groups 'high' in
nausea or catecholamine excretion. To increase the statistical
power groups were combined in the statistical analyses. Data
were analysed by the
' test and Student's t-test. Relative
risks and confidence intervals were also calculated (see Hursti
et al., 1992).
Results
Rating methods
On the chemotherapy day cohort 2 performed both category
and VAS ratings. making it possible to compare the covaria-
tion between the two methods. The two rating methods were
highly correlated V(1) = 22.24; P<0.0001], indicating that
they should result in similar grouping.
Cathecolamine excretion
The medians used to form groups 'low' and 'high' in
adrenaline excretion were 7.0 and 4.8 pmol min-' for cohorts
1 and 2 respectively. Corresponding numbers for noradren-
aline were 76.1 and 82.7 pmol min-'. Average noradrenaline
excretion was similar in cohorts 1 and 2. being 96.4 and
88.6 pmol min-' respectively. Adrenaline excretion was
similar in the two cohorts, being 7.4 and 5.3 pmol min'
respectively. Neither difference was statistically significant
[t<(61)<1.84; NS]. There was no apparent circadian varia-
tion in catecholamine excretion since early and late risers, as
defined by median split, had similar rates for both catechol-
amines (t<1; NS). Among the patients with 'high' nor-
adrenaline excretion, 18 had 'high' and 13 had 'low' excretion
of adrenaline, whereas among patients with 'low' adrenaline
excretion 18 showed 'low' and 13 'high' noradrenaline excre-
tion. Thus, excretion of the two catecholamines did not
covary significantly [X2(l) = 1.61; NS].
Pattern ofnausea and vomiting
Reflecting the effect of cisplatinum treatment, mean VAS
ratings of nausea were higher during the treatment day in644 N1. FREDRIKSON er a!
cohort 2 41.2. s.d. 26.4i than cohort 1 (8.9. s.d. 14.8).
[t (60) = 5.10: P<0.0001]. The patients in cohort 1 did not
experience any- Vomiting. except for one patient >-ho had a
single episode on the chemotherapy day. Therefore the
association betwxeen catecholamines and Xomitingz was
analysed for the patients in cohort 2 only.
CatecliolannneS related 0 tonausea and lht oitinig
Figure 1 displays the number of patients wxith hizh' and
low' nausea ratings as a function of night-time cate-
cholamine excretion. Noradrenaline significantly predicted
nausea during the first [7 (1) = 3.57: P= 0.03] and second
days after chemotherapy [f: (1) = 2.89: P = 0.04]. The
relatix-e risk (RR) for increased nausea >-as 1.6 w-ith a 950o
confidence interval (CI) of (1.0-2.5) for the first day after
chemotherapy and 1.7 (CI 0.9-3.3) for the second day. There
was a similar but non-significant trend [ (1) = 1.62:
P = 0.10] during the treatment day (RR = 1.4: CI 0.8-2.5)
(Fizure la>.
.Adrenaline >-as not consistently related to nausea since all
f tests wxere non-significant (Figure lb).
Twenty-six patients reported vromiting (Table lI>. but this
xwas not associated wxith catecholamine excretion.
Discussion
Pretreatment night-time noradrenaline excretion predicted
delayed chemotherapy-induced nausea. There are species
differences in emetic activity of catecholamines (Samardzic &
Beleslin. 1989). The findings of the present study indicate
that noradrenaline as compared with adrenaline is more
closelv linked to emesis in humans. High levels of
endogenous noradrenaline auzment the intensity of delayed
chemotherapy-induced nausea. The mechanism may be cen-
tral or peripheral in origin. We have previously demonstrated
that cortisol excretion is inversely related to the intensity of
nausea resultinz from chemotherapy. We (Fredrikson et al..
25 25 -
1992: Hursti et al.. 1993) sugzested that the anti-inflam-
matorv effect of cortisol could have antiemetic properties bv
preventing the release of serotonin in the gut or by sensitising
peripheral receptors involved in the action of antiemetic
drugs (Sagar. 1991). In addition. it is possible that cortisol
affects the blood-brain barrier permeabilitv to limit influx of
toxic substances to the central nervous svstem (CNS). Cor-
ticosteroids may also potentiate the antiemetic effects of. for
example. ondansetron by sensitising receptors in the CNNS
(Sagar. 1991). It might be speculated that noradrenaline. in
contrast to cortisol (Fredrikson et al.. 1992: Hursti et al..
1993). could promote the release of serotonin in the gut or
alternatively affect 5HT-receptor sensitivity. It is also con-
ceivable that high levels of noradrenaline are associated u-ith
receptor sensitivity in the CNS. In addition. adrenergic
activitv could facilitate the area postrema to circulating
emetozenic substances. This is in line with the suvzestion that
o-adrenergicallv mediated sensitisation of the area postrema
during chemotherapy treatment may result in enhanced
nausea (Borison. 1974. 1981). The fact that noradrenaline as
compared u-ith adrenaline Auas more closely related to nausea
in our study may implicate a CNS orinin of the obtained
Table II The mean number of emetic episodes as a function of
pretreatment night-time noradrenaline and adrenaline excretion in
patients from cohort _2 (see Table I. All the differences as a function
of catecholamine excretion are non-significant
\oradrenaline .4drenaline
ewcrerion e\Lcretion
Loi¶ High Loot High
n=2] n=' n 21 n =21
Chemotherapx day ' 3 3 3 2.3
First dav after 1 ' 2 2 2
chemotherapy
Second dav after CI I. 13.
chemotherapy
a
25 -
20 -
15
10
5 -
0
High noradrenaline Low noradrenaline
Chemotherapy day
25 -
c. 20 -
C,
4-
aL 15 -
0
0 10
.0
E
z 5
0
High adrenaline Low adrenaline
20 -
15
10
5
0
High noradrenaline Low noradrenaline
First day after chemotherapy
25 -
20 -
10
10 _
High adrenaline Low adrenaline
20 -
15
10-
5 -
High noradrenaline Low noradrenaline
Second day after chemotherapy
b
25 -
20 -
15 -
10
5-
0 -
High adrenaline Low adrenaline
Figure I Number of patients with high
noradrenaline (a) and adrenaline (b).
( _ ) and low' ( = ) nausea ratings as a function of pretreatment night-time
ci
a)
0.
.0
E
z
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effect. since noradrenaline. but not adrenaline, is found in
high concentrations in the area postrema (Leslie & Reynolds,
1993). This may explain why high levels of circulating
noradrenaline but not adrenaline were related to nausea in
our study. Thus. it is possible that noradrenaline sensitises
the area postrema to toxic substances more than does
adrenaline.
It has also been argued that peripheral and central nor-
adrenaline are correlated (Svensson, 1987). During conditions
of stress there are parallel changes in peripheral sympathetic
activity and in the locus coeruleus in the brain, the network
of which accounts for most of the brain noradrenaline (Sven-
sson, 1987). Locus coeruleus activity is influenced by both
external sensory and internal vegetative events (Svensson,
1987), and the hypothesis has been advanced that a high
activity facilitates performance of the gastrointestinal system
(Elam et al., 1986). Since locus coeruleus activation is an
integrated part of the anxiety response, this brain structure
may be the final common pathway that mediates the well-
known (Andrykowski et al., 1985) relationship between anxi-
ety and nausea.
Delayed as compared with acute nausea was more strongly
related to adrenergic activity. Since the nausea intensity was
similar during acute and delayed nausea, it is not likely that
individual modulating factors are of less importance only
because nausea is more severe during chemotherapy. Instead.
data may indicate that factors associated with adrenergic
activation are prognostic specifically for delayed nausea.
It has been demonstrated that exogenous administration of
catecholamines results in improved conditionability in
animals (Weinberger et al., 1984). Thus, to the extent that
delayed nausea in part reflects conditioned nausea even in the
second cycle of chemotherapy (Morrow, 1982; Andrykowski
et al.. 1985; Burish & Carey, 1986: Hursti et al.. 1992). the
data of the present study may also indicate that noradren-
aline facilitates conditioning of nausea. We did not assess to
what extent delayed nausea reflected conditioned nausea. and
at present this must remain speculation.
We conclude that individual differences in delayed nausea
after chemotherapy are influenced by neuroendocrine factors
and linked both to the pituitary-adrenal cortical axis as
indexed by cortisol (Fredrikson et al., 1992; Hursti et al.,
1993) and to the sympathetic-adrenal medullary axis as
reflected in noradrenaline. This may serve to tailor treatment
strategies for patients likely to experience severe delayed
emesis. It should support further study of neuroendocrine
mechanisms involved in modulating chemotherapy emesis
and particularly the possible role of the area postrema and
the locus coeruleus and their interaction.
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